Immune System
|

Development of a new product for the topical treatment of hair loss based on the soluble CD83 molecule

Institution: Department of Immune Modulation at the Department of Dermatology University Hospital Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg
Applicant: Prof. Dr. Alexander Steinkasserer
Funding line:
Translational Research
Image
Hormon-induced hair loss is induced by dihydro-testosterone which damages hair follicles. The application of sCD83 gives rise to pro-regeneraitve macrophages as well as regulatory T cells, which promote the formation of new hair follicles.
(© D. Royzman/ A. Steinkasserer, Immunmodulatorische Abteilung, UKER)

Project partner:

Frau Prof. Dagmar Fischer, Lehrstuhl für Pharmazeutische Technologie und Biopharmazie, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

 

Project:

The aim of this project is the development of an new product for the topical treatment of androgenetic- as well as hormone-mediated hair loss, based on the soluble CD83 protein. Worldwide, up to 70% of men and up to 40% of women suffer from androgenetic hair loss. In addition, approx. 2% of the world population suffers from the autoimmune-mediated hair loss, also known as Alopecia areata. However, for both forms of hair loss only limited effective and no curative treatment options are available. Thus, for both major forms of hair loss there is a huge medical need for new and better treatment option. Interestingly, in preclinical studies we have shown that the soluble CD83 molecule (sCD83) induces new hair growth in mice. With the support of the ForTra gGmbH we aim to develop new treatment strategies for patients suffering for hair loss.

Here you can find further information.

Image
From left to right: Prof. Alexander Steinkasserer and coworker of the Department of Immune Modulation
(© Immunmodulatorische Abteilung, UKER)